{"title":"Long-Term Sequential Therapy for Pregnancy- and Lactation-Associated Osteoporosis With Multiple Vertebral Fractures: A Case Report of Over 5 Years.","authors":"Kaneyuki Tsuchimochi, Hiroe Tsuchimochi","doi":"10.1155/crog/5696865","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pregnancy- and lactation-associated osteoporosis (PLO) is a rare condition that may cause multiple vertebral fractures during late pregnancy or the postpartum period. Evidence regarding treatment strategies remains limited, particularly regarding long-term outcomes of sequential regimens combining anabolic and antiresorptive therapies.</p><p><strong>Case presentation: </strong>A 37-year-old woman developed low back pain 3 months postpartum and was diagnosed with PLO accompanied by multiple acute and chronic vertebral fractures. Breastfeeding was discontinued, and initial treatment with vitamin D analogs and bisphosphonate therapy was selected based on clinical and patient-specific considerations, including documented efficacy in PLO, the absence of reproductive safety concerns, and patient preferences. Despite early improvement, lumbar spine Z-score remained persistently low at -3.0, and therapy was sequentially transitioned to daily teriparatide for 2 years, romosozumab for 1 year, and denosumab for maintenance. Over 5 years and 7 months, lumbar spine and femoral neck bone mineral density increased by 53.4% and 26.1%, respectively. No new fractures occurred, and serial bone turnover markers demonstrated appropriate anabolic and antiresorptive responses at each phase of therapy.</p><p><strong>Conclusion: </strong>This case highlights a successful long-term sequential treatment strategy for PLO involving bisphosphonate, teriparatide, romosozumab, and denosumab in a patient without desire for further pregnancy, without reproductive safety constraints. The individualized sequential approach developed through patient education and shared decision-making may help achieve sustained improvements in bone mineral density and prevent refracture in patients at very high fracture risk, particularly when an anabolic-first strategy is not initially feasible.</p>","PeriodicalId":9610,"journal":{"name":"Case Reports in Obstetrics and Gynecology","volume":"2026 ","pages":"5696865"},"PeriodicalIF":0.8000,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13261773/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Obstetrics and Gynecology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crog/5696865","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Pregnancy- and lactation-associated osteoporosis (PLO) is a rare condition that may cause multiple vertebral fractures during late pregnancy or the postpartum period. Evidence regarding treatment strategies remains limited, particularly regarding long-term outcomes of sequential regimens combining anabolic and antiresorptive therapies.
Case presentation: A 37-year-old woman developed low back pain 3 months postpartum and was diagnosed with PLO accompanied by multiple acute and chronic vertebral fractures. Breastfeeding was discontinued, and initial treatment with vitamin D analogs and bisphosphonate therapy was selected based on clinical and patient-specific considerations, including documented efficacy in PLO, the absence of reproductive safety concerns, and patient preferences. Despite early improvement, lumbar spine Z-score remained persistently low at -3.0, and therapy was sequentially transitioned to daily teriparatide for 2 years, romosozumab for 1 year, and denosumab for maintenance. Over 5 years and 7 months, lumbar spine and femoral neck bone mineral density increased by 53.4% and 26.1%, respectively. No new fractures occurred, and serial bone turnover markers demonstrated appropriate anabolic and antiresorptive responses at each phase of therapy.
Conclusion: This case highlights a successful long-term sequential treatment strategy for PLO involving bisphosphonate, teriparatide, romosozumab, and denosumab in a patient without desire for further pregnancy, without reproductive safety constraints. The individualized sequential approach developed through patient education and shared decision-making may help achieve sustained improvements in bone mineral density and prevent refracture in patients at very high fracture risk, particularly when an anabolic-first strategy is not initially feasible.